Amalgamated Bank Lowers Position in Moderna, Inc. (NASDAQ:MRNA)

Amalgamated Bank reduced its stake in Moderna, Inc. (NASDAQ:MRNA) by 1.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 65,674 shares of the company’s stock after selling 1,101 shares during the period. Amalgamated Bank’s holdings in Moderna were worth $4,389,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Janney Montgomery Scott LLC lifted its holdings in shares of Moderna by 38.6% in the 1st quarter. Janney Montgomery Scott LLC now owns 14,373 shares of the company’s stock worth $1,532,000 after acquiring an additional 4,003 shares during the last quarter. Empirical Finance LLC grew its stake in shares of Moderna by 4.7% in the first quarter. Empirical Finance LLC now owns 8,975 shares of the company’s stock valued at $956,000 after buying an additional 399 shares in the last quarter. Empowered Funds LLC raised its holdings in shares of Moderna by 26.8% in the 1st quarter. Empowered Funds LLC now owns 4,276 shares of the company’s stock valued at $456,000 after buying an additional 904 shares during the period. SG Americas Securities LLC lifted its stake in Moderna by 32.8% during the 1st quarter. SG Americas Securities LLC now owns 79,310 shares of the company’s stock worth $8,451,000 after acquiring an additional 19,609 shares in the last quarter. Finally, Oppenheimer & Co. Inc. boosted its holdings in Moderna by 25.6% during the 1st quarter. Oppenheimer & Co. Inc. now owns 40,305 shares of the company’s stock valued at $4,295,000 after acquiring an additional 8,214 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insiders Place Their Bets

In related news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at $571,440.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Moderna news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares in the company, valued at approximately $571,440.60. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares in the company, valued at approximately $682,754. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 3,184 shares of company stock valued at $238,531. 15.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on MRNA. HSBC upgraded shares of Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price target on the stock in a research note on Wednesday, August 28th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $75.00 target price on shares of Moderna in a research note on Thursday, September 19th. Barclays decreased their price target on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research report on Friday. The Goldman Sachs Group cut their price objective on Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research report on Monday, September 16th. Finally, Piper Sandler decreased their target price on Moderna from $157.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, September 13th. Two research analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Moderna currently has an average rating of “Hold” and a consensus price target of $93.18.

Moderna Stock Performance

Shares of Moderna stock opened at $46.83 on Friday. The firm has a market capitalization of $18.00 billion, a P/E ratio of -3.04 and a beta of 1.69. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a 52 week low of $46.57 and a 52 week high of $170.47. The firm’s 50 day moving average is $61.85 and its two-hundred day moving average is $99.22.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same period last year, the firm posted ($1.39) EPS. The company’s revenue was up 3.8% on a year-over-year basis. Research analysts forecast that Moderna, Inc. will post -9.89 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.